Patent Assignment
Reel/Frame 072249/0280
Release of Security Interest (Reel/Frame 064748/0552)
Recorded: 2025-07-24
Pages: 68
Assignor
TAO TALENTS, LLC
Executed: 2025-07-17
Assignee
BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties
(79)
CDK2 Inhibitors
Application:
63/478,407 →
CDK2 Inhibitors
Application:
63/496,146 →
Solid Forms of CDK2 Inhibitor
Application:
63/478,413 →
CDK2 Inhibitors
Application:
63/478,410 →
CDK2 Inhibitors for Treatment of Cancer
Application:
63/484,383 →
CDK2 Inhibitors for Treatment of Cancer
Application:
63/505,507 →
Egfr Inhibitors
Compositions and Methods for Treating Kit- and Pdgfra-Mediated Diseases
Application:
18/031,714 →
Publication:
US 2023/0391780
Compositions and Methods for Treating Kit- and Pdgfra-Mediated Diseases
Application:
18/031,688 →
Publication:
US 2024/0010652
Egfr Inhibitors
Pyrimidine Compounds, Compositions, and Medicinal Applications Thereof
Application:
18/033,954 →
Publication:
US 2024/0051945
Pyrimidine Compounds, Compositions, and Medicinal Applications Thereof
Application:
18/033,931 →
Publication:
US 2023/0416232
Egfr Inhibitors for Treatment of Cancer
Application:
63/417,489 →
Egfr Inhibitors for Treatment of Cancer
Application:
63/421,516 →
Egfr Inhibitors
Application:
63/406,386 →
Wild Type Kit Inhibitors
Application:
63/428,804 →
Wild Type Kit Inhibitors
Application:
63/445,787 →
Egfr Inhibitors for Treatment of Cancer
Application:
63/421,523 →
Egfr Inhibitors for Treatment of Cancer
Application:
63/440,804 →
Egfr Inhibitors for Treatment of Cancer
Application:
63/468,875 →
Inhibitors of Activin Receptor-Like Kinase
Method of Preparing Pralsetinib
Application:
18/255,402 →
Publication:
US 2024/0059672
Pralsetinib Pharmaceutical Compositions
Application:
18/000,166 →
Publication:
US 2023/0203009
Solid Forms of Pralsetinib
CDK2 Inhibitors
CDK2 Inhibitors
Application:
63/478,404 →
MAP4K1 Inhibitors
MAP4K1 Inhibitors
GSK3a INHIBITORS AND METHODS OF USE THEREOF
Application:
63/465,428 →
Compositions Useful for Treating Disorders Related to Kit
Dosing Regimens of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazin-1-Yl)Pyrimidin-5-Yl)Ethan-1-Amine for Treatment of Indolent Systemic Mastocytosis
Crystalline Forms of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine and Methods of Making
Methods for Treating Systemic Mastocytosis and Gastrointestinal Stromal Tumors
Application:
18/199,118 →
Publication:
US 2024/0382493
Substituted Pyrimidine Compounds, Compositions and Medicinal Applications Thereof
Inhibitors of the Fibroblast Growth Factor Receptor
PCT:
PCT/US2013/050106 ↗
Inhibitors of the Fibroblast Growth Factor Receptor
PCT:
PCT/US2014/061974 ↗
Inhibitors of the Fibroblast Growth Factor Receptor
PCT:
PCT/US2015/011424 ↗
Inhibitors of Ret
PCT:
PCT/US2016/016808 ↗
Inhibitors of Ret
PCT:
PCT/US2017/022969 ↗
Compounds Useful for Treating Disorders Related to Ret
PCT:
PCT/US2017/043340 ↗
Compounds Useful for Treating Disorders Related to Ret
PCT:
PCT/US2017/043964 ↗
PIK3C2G Fusions
PCT:
PCT/US2014/048869 ↗
NTRK2 Fusions
PCT:
PCT/US2014/048881 ↗
PIK3CA Fusions
PCT:
PCT/US2015/026501 ↗
Met Fusions
PCT:
PCT/US2015/026505 ↗
RAF1 Fusions
PCT:
PCT/US2015/035019 ↗
PKN1 Fusions
PCT:
PCT/US2015/035020 ↗
Tert Fusions
PCT:
PCT/US2015/040557 ↗
Prkc Fusions
PCT:
PCT/US2015/040560 ↗
Fgr Fusions
PCT:
PCT/US2015/040553 ↗
Prkacb Fusions
PCT:
PCT/US2015/061073 ↗
Compounds and Compositions Useful for Treating Disorders Related to Kit and Pdgfr
PCT:
PCT/US2018/025193 ↗
Egfr Inhibitors
PCT:
PCT/US2020/066629 ↗
Egfr Inhibitors
PCT:
PCT/US2023/017384 ↗
Fused Pyrimidine Compounds, Compositions and Medicinal Applications Thereof
PCT:
PCT/US2020/052953 ↗
Egfr Inhibitors for Treatment of Cancer
PCT:
PCT/US2023/015849 ↗
Salt and Crystal Forms of an Epidermal Growth Factor Receptor Inhibitor
PCT:
PCT/US2023/020925 ↗
Inhibitors of Activin Receptor-Like Kinase
PCT:
PCT/US2017/027775 ↗
Inhibitors of Activin Receptor-Like Kinase
PCT:
PCT/US2018/056589 ↗
Salt and Crystal Forms of an Activin Receptor-Like Kinase Inhibitor
PCT:
PCT/US2020/045847 ↗
Process for Preparing an Activin Receptor-Like Kinase Inhibitor
PCT:
PCT/US2020/053904 ↗
Ret Inhibitor
PCT:
PCT/US2019/025655 ↗
Treatment of Egfr-Mutant Cancer
PCT:
PCT/US2019/045919 ↗
Inhibitors of Ret
PCT:
PCT/US2016/059879 ↗
CDK2 Inhibitors and Methods of Making and Using Same
PCT:
PCT/US2022/080165 ↗
CDK2 Inhibitors and Methods of Making and Using Same
PCT:
PCT/US2022/080199 ↗
MAP4K1 Inhibitors
PCT:
PCT/US2022/073697 ↗
MAP4K1 Inhibitors
PCT:
PCT/US2022/073718 ↗
Kit Inhibitors
PCT:
PCT/US2023/019090 ↗
Compositions Useful for Treating Disorders Related to Kit
PCT:
PCT/US2014/060746 ↗
Crystalline Forms of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine and Methods of Making
PCT:
PCT/US2020/027724 ↗
Kit Mutations
PCT:
PCT/US2019/060769 ↗
Compositions and Methods for Treating Kit- and Pdgfra-Mediated Diseases
PCT:
PCT/US2020/027177 ↗
Treatment of Eosinophilic Disorder
PCT:
PCT/US2020/054221 ↗
Treatment of Mast Cell Diseases and Eosinophilic Disorders
PCT:
PCT/US2020/058632 ↗
Compositions Useful for Treating Disorders Related to Kit
PCT:
PCT/US2014/027008 ↗
Compositions Useful for Treating Disorders Related to Kit
PCT:
PCT/US2014/061211 ↗
Compositions Useful for Treating Disorders Related to Kit
PCT:
PCT/US2015/043624 ↗
Compositions Useful for Treating Disorders Related to Kit and Pdfgr
PCT:
PCT/US2016/043301 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 8, 2022
From: BROOIJMANS, NATASJA; BRUBAKER, JASON D.; CAMPBELL, JOHN EMMERSON; DE SAVI, CHRISTOPHER
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 061025/0178 →
Assignment of Assignor's Interest
Sep 8, 2022
From: AHMAD, OMAR; CAMPBELL, JOHN EMMERSON; DINEEN, THOMAS A.; ENO, MEREDITH SUZANNE
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 061025/0537 →
Assignment of Assignor's Interest
Oct 28, 2022
From: FERNANDO, DILINIE PRASADHINI
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 061578/0185 →
Assignment of Assignor's Interest
Nov 9, 2022
From: HODOUS, BRIAN L.; KIM, JOSEPH L.; WILSON, KEVIN J.; WILSON, DOUGLAS
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 061711/0030 →
Assignment of Assignor's Interest
Dec 16, 2022
From: BRUBAKER, JASON D.; MIDUTURU, CHANDRASEKHAR V.; BURKE, MICHAEL J.; DINEEN, THOMAS A.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062150/0587 →
Assignment of Assignor's Interest
Feb 28, 2023
From: HAIDLE, ANDREW MARC
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062834/0078 →
Assignment of Assignor's Interest
Feb 28, 2023
From: HAIDLE, ANDREW MARC
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062834/0050 →
Assignment of Assignor's Interest
Feb 28, 2023
From: CONTI, CHIARA; ZALUTSKAYA, ALENA
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062823/0013 →
Assignment of Assignor's Interest
Feb 28, 2023
From: MAR, BRENTON
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062822/0823 →
Assignment of Assignor's Interest
Mar 1, 2023
From: MIDUTURU, CHANDRASEKHAR V.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 062838/0202 →
Assignment of Assignor's Interest
Mar 17, 2023
From: BRUBAKER, JASON D; MIDUTURU, CHANDRASEKHAR V.; BURKE, MICHAEL J; DINEEN, THOMAS A
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063116/0877 →
Assignment of Assignor's Interest
Mar 21, 2023
From: CONTI, CHIARA; ZALUTSKAYA, ALENA
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063045/0577 →
Assignment of Assignor's Interest
Apr 4, 2023
From: BRUBAKER, JASON D.; CLOSE, JOSHUA T.; DINEEN, THOMAS A.; MIDUTURU, CHANDRASEKHAR V.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063212/0922 →
Assignment of Assignor's Interest
Apr 13, 2023
From: LYDON, NICHOLAS
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063314/0744 →
Assignment of Assignor's Interest
Apr 13, 2023
From: DINEEN, THOMAS A.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 063314/0771 →
Assignment of Assignor's Interest
Aug 23, 2023
From: WILSON, DOUGLAS; BIFULCO, NEIL, JR.; BROOIJMANS, NATASJA; KIM, JOSEPH L.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 064680/0199 →
Security Interest
Aug 29, 2023
From: BLUEPRINT MEDICINES CORPORATION
To: TAO TALENTS, LLC
Reel/Frame 064748/0552 →
Assignment of Assignor's Interest
Oct 30, 2023
From: ANKROM, WENDY; MAR, BRENTON; PANDY, ANJALI; PEARSON, PAUL
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065391/0823 →
Assignment of Assignor's Interest
Oct 30, 2023
From: MAR, BRENTON; PANDY, ANJALI; PEARSON, PAUL; ZALUTSKAYA, ALENA
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065391/0672 →
Assignment of Assignor's Interest
Oct 30, 2023
From: MAR, BRENTON; PANDY, ANJALI; PEARSON, PAUL; ZALUTSKAYA, ALENA
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065391/0648 →
Assignment of Assignor's Interest
Nov 8, 2023
From: ERBACH, RACHEL LAUREN; GUO, JIAN; LOBBARDI, RIADH; RINNE, MIKAEL L.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065497/0026 →
Assignment of Assignor's Interest
Nov 10, 2023
From: BRUBAKER, JASON D.; BURKE, MICHAEL; DINEEN, THOMAS A.; ENO, MEREDITH SUZANNE
To: BLUEPRIINT MEDICINES CORPORATION
Reel/Frame 065526/0882 →
Assignment of Assignor's Interest
Nov 10, 2023
From: BIFULCO, NEIL, JR.; BROOIJMANS, NATASJA; FANG, CHENG; KIM, JOSEPH L.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065528/0351 →
Assignment of Assignor's Interest
Nov 13, 2023
From: RAMSDEN, PHILIP D.; BIFULCO, NEIL, JR.; BROOIJMANS, NATASJA; KIM, JOSEPH L.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065542/0273 →
Assignment of Assignor's Interest
Nov 13, 2023
From: RAMSDEN, PHILIP D.; BIFULCO, NEIL, JR.; BROOIJMANS, NATASJA; KIM, JOSEPH L.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 065542/0333 →